Compile Data Set for Download or QSAR
Report error Found 207 Enz. Inhib. hit(s) with all data for entry = 1897
TargetProto-oncogene Wnt-1(Human)
Samumed

US Patent
LigandPNGBDBM346341(US10202377, Compound 367)
Affinity DataIC50: 3.5nMAssay Description:The screening assay for Wnt activity is described as follows. Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., col...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/2/2019
Entry Details
US Patent

TargetProto-oncogene Wnt-1(Human)
Samumed

US Patent
LigandPNGBDBM346315(US10202377, Compound 269)
Affinity DataIC50: 4.20nMAssay Description:The screening assay for Wnt activity is described as follows. Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., col...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/2/2019
Entry Details
US Patent

TargetProto-oncogene Wnt-1(Human)
Samumed

US Patent
LigandPNGBDBM346283(US10202377, Compound 82)
Affinity DataIC50: 4.5nMAssay Description:The screening assay for Wnt activity is described as follows. Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., col...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/2/2019
Entry Details
US Patent

TargetProto-oncogene Wnt-1(Human)
Samumed

US Patent
LigandPNGBDBM346318(US10202377, Compound 280)
Affinity DataIC50: 6.20nMAssay Description:The screening assay for Wnt activity is described as follows. Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., col...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/2/2019
Entry Details
US Patent

TargetProto-oncogene Wnt-1(Human)
Samumed

US Patent
LigandPNGBDBM346320(US10202377, Compound 288)
Affinity DataIC50: 6.80nMAssay Description:The screening assay for Wnt activity is described as follows. Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., col...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/2/2019
Entry Details
US Patent

TargetProto-oncogene Wnt-1(Human)
Samumed

US Patent
LigandPNGBDBM346309(US10202377, Compound 238)
Affinity DataIC50: 7.70nMAssay Description:The screening assay for Wnt activity is described as follows. Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., col...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/2/2019
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Samumed

US Patent
LigandPNGBDBM346319(US10202377, Compound 283)
Affinity DataEC50:  9nMAssay Description:Compound Screening: Each compound was dissolved in DMSO as a 10 mM stock and used to prepare compound source plates. Serial dilution (1:2, 11-point d...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/2/2019
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Samumed

US Patent
LigandPNGBDBM346320(US10202377, Compound 288)
Affinity DataEC50:  9nMAssay Description:Compound Screening: Each compound was dissolved in DMSO as a 10 mM stock and used to prepare compound source plates. Serial dilution (1:2, 11-point d...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/2/2019
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Samumed

US Patent
LigandPNGBDBM346316(US10202377, Compound 271)
Affinity DataEC50:  9nMAssay Description:Compound Screening: Each compound was dissolved in DMSO as a 10 mM stock and used to prepare compound source plates. Serial dilution (1:2, 11-point d...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/2/2019
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Samumed

US Patent
LigandPNGBDBM346317(US10202377, Compound 277)
Affinity DataEC50:  9nMAssay Description:Compound Screening: Each compound was dissolved in DMSO as a 10 mM stock and used to prepare compound source plates. Serial dilution (1:2, 11-point d...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/2/2019
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Samumed

US Patent
LigandPNGBDBM346324(US10202377, Compound 298)
Affinity DataEC50:  9nMAssay Description:Compound Screening: Each compound was dissolved in DMSO as a 10 mM stock and used to prepare compound source plates. Serial dilution (1:2, 11-point d...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/2/2019
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Samumed

US Patent
LigandPNGBDBM346321(US10202377, Compound 292)
Affinity DataEC50:  9nMAssay Description:Compound Screening: Each compound was dissolved in DMSO as a 10 mM stock and used to prepare compound source plates. Serial dilution (1:2, 11-point d...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/2/2019
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Samumed

US Patent
LigandPNGBDBM346322(US10202377, Compound 294)
Affinity DataEC50:  9nMAssay Description:Compound Screening: Each compound was dissolved in DMSO as a 10 mM stock and used to prepare compound source plates. Serial dilution (1:2, 11-point d...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/2/2019
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Samumed

US Patent
LigandPNGBDBM346308(US10202377, Compound 234)
Affinity DataEC50:  9nMAssay Description:Compound Screening: Each compound was dissolved in DMSO as a 10 mM stock and used to prepare compound source plates. Serial dilution (1:2, 11-point d...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/2/2019
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Samumed

US Patent
LigandPNGBDBM346314(US10202377, Compound 268)
Affinity DataEC50:  9nMAssay Description:Compound Screening: Each compound was dissolved in DMSO as a 10 mM stock and used to prepare compound source plates. Serial dilution (1:2, 11-point d...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/2/2019
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Samumed

US Patent
LigandPNGBDBM346313(US10202377, Compound 265)
Affinity DataEC50:  9nMAssay Description:Compound Screening: Each compound was dissolved in DMSO as a 10 mM stock and used to prepare compound source plates. Serial dilution (1:2, 11-point d...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/2/2019
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Samumed

US Patent
LigandPNGBDBM346341(US10202377, Compound 367)
Affinity DataEC50:  9nMAssay Description:Compound Screening: Each compound was dissolved in DMSO as a 10 mM stock and used to prepare compound source plates. Serial dilution (1:2, 11-point d...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/2/2019
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Samumed

US Patent
LigandPNGBDBM346271(US10202377, Compound 13)
Affinity DataEC50:  9nMAssay Description:Compound Screening: Each compound was dissolved in DMSO as a 10 mM stock and used to prepare compound source plates. Serial dilution (1:2, 11-point d...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/2/2019
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Samumed

US Patent
LigandPNGBDBM346269(US10202377, Compound 1)
Affinity DataEC50:  9nMAssay Description:Compound Screening: Each compound was dissolved in DMSO as a 10 mM stock and used to prepare compound source plates. Serial dilution (1:2, 11-point d...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/2/2019
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Samumed

US Patent
LigandPNGBDBM346343(US10202377, Compound 379)
Affinity DataEC50:  9nMAssay Description:Compound Screening: Each compound was dissolved in DMSO as a 10 mM stock and used to prepare compound source plates. Serial dilution (1:2, 11-point d...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/2/2019
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Samumed

US Patent
LigandPNGBDBM346336(US10202377, Compound 337)
Affinity DataEC50:  9nMAssay Description:Compound Screening: Each compound was dissolved in DMSO as a 10 mM stock and used to prepare compound source plates. Serial dilution (1:2, 11-point d...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/2/2019
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Samumed

US Patent
LigandPNGBDBM346333(US10202377, Compound 325)
Affinity DataEC50:  9nMAssay Description:Compound Screening: Each compound was dissolved in DMSO as a 10 mM stock and used to prepare compound source plates. Serial dilution (1:2, 11-point d...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/2/2019
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Samumed

US Patent
LigandPNGBDBM346358(US10202377, Compound 448)
Affinity DataEC50:  9nMAssay Description:Compound Screening: Each compound was dissolved in DMSO as a 10 mM stock and used to prepare compound source plates. Serial dilution (1:2, 11-point d...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/2/2019
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Samumed

US Patent
LigandPNGBDBM346283(US10202377, Compound 82)
Affinity DataEC50:  9nMAssay Description:Compound Screening: Each compound was dissolved in DMSO as a 10 mM stock and used to prepare compound source plates. Serial dilution (1:2, 11-point d...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/2/2019
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Samumed

US Patent
LigandPNGBDBM346356(US10202377, Compound 439)
Affinity DataEC50:  9nMAssay Description:Compound Screening: Each compound was dissolved in DMSO as a 10 mM stock and used to prepare compound source plates. Serial dilution (1:2, 11-point d...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/2/2019
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Samumed

US Patent
LigandPNGBDBM346357(US10202377, Compound 442)
Affinity DataEC50:  9nMAssay Description:Compound Screening: Each compound was dissolved in DMSO as a 10 mM stock and used to prepare compound source plates. Serial dilution (1:2, 11-point d...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/2/2019
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Samumed

US Patent
LigandPNGBDBM346286(US10202377, Compound 93)
Affinity DataEC50:  9nMAssay Description:Compound Screening: Each compound was dissolved in DMSO as a 10 mM stock and used to prepare compound source plates. Serial dilution (1:2, 11-point d...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/2/2019
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Samumed

US Patent
LigandPNGBDBM346287(US10202377, Compound 101)
Affinity DataEC50:  9nMAssay Description:Compound Screening: Each compound was dissolved in DMSO as a 10 mM stock and used to prepare compound source plates. Serial dilution (1:2, 11-point d...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/2/2019
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Samumed

US Patent
LigandPNGBDBM346285(US10202377, Compound 90)
Affinity DataEC50:  9nMAssay Description:Compound Screening: Each compound was dissolved in DMSO as a 10 mM stock and used to prepare compound source plates. Serial dilution (1:2, 11-point d...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/2/2019
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Samumed

US Patent
LigandPNGBDBM346353(US10202377, Compound 427)
Affinity DataEC50:  9nMAssay Description:Compound Screening: Each compound was dissolved in DMSO as a 10 mM stock and used to prepare compound source plates. Serial dilution (1:2, 11-point d...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/2/2019
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Samumed

US Patent
LigandPNGBDBM346279(US10202377, Compound 55)
Affinity DataEC50:  9nMAssay Description:Compound Screening: Each compound was dissolved in DMSO as a 10 mM stock and used to prepare compound source plates. Serial dilution (1:2, 11-point d...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/2/2019
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Samumed

US Patent
LigandPNGBDBM346354(US10202377, Compound 433)
Affinity DataEC50:  9nMAssay Description:Compound Screening: Each compound was dissolved in DMSO as a 10 mM stock and used to prepare compound source plates. Serial dilution (1:2, 11-point d...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/2/2019
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Samumed

US Patent
LigandPNGBDBM346351(US10202377, Compound 421)
Affinity DataEC50:  9nMAssay Description:Compound Screening: Each compound was dissolved in DMSO as a 10 mM stock and used to prepare compound source plates. Serial dilution (1:2, 11-point d...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/2/2019
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Samumed

US Patent
LigandPNGBDBM346300(US10202377, Compound 190)
Affinity DataEC50:  9nMAssay Description:Compound Screening: Each compound was dissolved in DMSO as a 10 mM stock and used to prepare compound source plates. Serial dilution (1:2, 11-point d...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/2/2019
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Samumed

US Patent
LigandPNGBDBM346298(US10202377, Compound 181)
Affinity DataEC50:  9nMAssay Description:Compound Screening: Each compound was dissolved in DMSO as a 10 mM stock and used to prepare compound source plates. Serial dilution (1:2, 11-point d...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/2/2019
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Samumed

US Patent
LigandPNGBDBM346301(US10202377, Compound 196)
Affinity DataEC50:  9nMAssay Description:Compound Screening: Each compound was dissolved in DMSO as a 10 mM stock and used to prepare compound source plates. Serial dilution (1:2, 11-point d...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/2/2019
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Samumed

US Patent
LigandPNGBDBM346302(US10202377, Compound 202)
Affinity DataEC50:  9nMAssay Description:Compound Screening: Each compound was dissolved in DMSO as a 10 mM stock and used to prepare compound source plates. Serial dilution (1:2, 11-point d...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/2/2019
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Samumed

US Patent
LigandPNGBDBM346365(US10202377, Compound 939)
Affinity DataEC50:  9nMAssay Description:Compound Screening: Each compound was dissolved in DMSO as a 10 mM stock and used to prepare compound source plates. Serial dilution (1:2, 11-point d...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/2/2019
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Samumed

US Patent
LigandPNGBDBM346296(US10202377, Compound 169)
Affinity DataEC50:  9nMAssay Description:Compound Screening: Each compound was dissolved in DMSO as a 10 mM stock and used to prepare compound source plates. Serial dilution (1:2, 11-point d...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/2/2019
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Samumed

US Patent
LigandPNGBDBM346383(US10202377, Compound 1350)
Affinity DataEC50:  9nMAssay Description:Compound Screening: Each compound was dissolved in DMSO as a 10 mM stock and used to prepare compound source plates. Serial dilution (1:2, 11-point d...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/2/2019
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Samumed

US Patent
LigandPNGBDBM346294(US10202377, Compound 154)
Affinity DataEC50:  9nMAssay Description:Compound Screening: Each compound was dissolved in DMSO as a 10 mM stock and used to prepare compound source plates. Serial dilution (1:2, 11-point d...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/2/2019
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Samumed

US Patent
LigandPNGBDBM346379(US10202377, Compound 953)
Affinity DataEC50:  9nMAssay Description:Compound Screening: Each compound was dissolved in DMSO as a 10 mM stock and used to prepare compound source plates. Serial dilution (1:2, 11-point d...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/2/2019
Entry Details
US Patent

TargetProto-oncogene Wnt-1(Human)
Samumed

US Patent
LigandPNGBDBM346351(US10202377, Compound 421)
Affinity DataIC50: 10nMAssay Description:The screening assay for Wnt activity is described as follows. Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., col...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/2/2019
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Samumed

US Patent
LigandPNGBDBM346272(US10202377, Compound 20)
Affinity DataEC50:  10nMAssay Description:Compound Screening: Each compound was dissolved in DMSO as a 10 mM stock and used to prepare compound source plates. Serial dilution (1:2, 11-point d...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/2/2019
Entry Details
US Patent

TargetProto-oncogene Wnt-1(Human)
Samumed

US Patent
LigandPNGBDBM346339(US10202377, Compound 358)
Affinity DataIC50: 11.6nMAssay Description:The screening assay for Wnt activity is described as follows. Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., col...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/2/2019
Entry Details
US Patent

TargetProto-oncogene Wnt-1(Human)
Samumed

US Patent
LigandPNGBDBM346324(US10202377, Compound 298)
Affinity DataIC50: 12.9nMAssay Description:The screening assay for Wnt activity is described as follows. Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., col...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/2/2019
Entry Details
US Patent

TargetProto-oncogene Wnt-1(Human)
Samumed

US Patent
LigandPNGBDBM346285(US10202377, Compound 90)
Affinity DataIC50: 13.9nMAssay Description:The screening assay for Wnt activity is described as follows. Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., col...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/2/2019
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Samumed

US Patent
LigandPNGBDBM346342(US10202377, Compound 373)
Affinity DataEC50:  14nMAssay Description:Compound Screening: Each compound was dissolved in DMSO as a 10 mM stock and used to prepare compound source plates. Serial dilution (1:2, 11-point d...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/2/2019
Entry Details
US Patent

TargetProto-oncogene Wnt-1(Human)
Samumed

US Patent
LigandPNGBDBM346332(US10202377, Compound 321)
Affinity DataIC50: 16.3nMAssay Description:The screening assay for Wnt activity is described as follows. Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., col...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/2/2019
Entry Details
US Patent

TargetProto-oncogene Wnt-1(Human)
Samumed

US Patent
LigandPNGBDBM346326(US10202377, Compound 306)
Affinity DataIC50: 16.8nMAssay Description:The screening assay for Wnt activity is described as follows. Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., col...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/2/2019
Entry Details
US Patent

Displayed 1 to 50 (of 207 total ) | Next | Last >>
Jump to: